Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting -- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...

Trevena Reports Fourth Quarter and Full Year 2018 Results — Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA —  — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...